Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.3%

1 terminated/withdrawn out of 23 trials

Success Rate

95.5%

+8.9% vs industry average

Late-Stage Pipeline

39%

9 trials in Phase 3/4

Results Transparency

33%

7 of 21 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 2
8(34.8%)
Phase 3
7(30.4%)
Phase 1
6(26.1%)
Phase 4
2(8.7%)
23Total
Phase 2(8)
Phase 3(7)
Phase 1(6)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT06423703Phase 3Completed

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

Role: lead

NCT06545097Phase 3Completed

A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty

Role: lead

NCT06453265Phase 1Completed

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

Role: lead

NCT07044609Phase 4Not Yet Recruiting

A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD

Role: collaborator

NCT05491785Phase 1Completed

Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.

Role: lead

NCT03834766Phase 3Completed

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

Role: lead

NCT05256108Phase 1Completed

Assessment of Abuse Potential of Cebranopadol in Humans

Role: lead

NCT04027361Phase 2Completed

Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)

Role: lead

NCT01939366Phase 2Completed

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

Role: lead

NCT00872885Phase 2Completed

Bunionectomy Trial With GRT6005

Role: lead

NCT00878293Phase 2Completed

Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic

Role: lead

NCT01964378Phase 3Terminated

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer

Role: lead

NCT01347671Phase 2Completed

Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy

Role: lead

NCT01725087Phase 2Completed

Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.

Role: lead

NCT01357837Phase 2Completed

Assessment of GRT6005 in Painful Osteoarthritis of the Knee

Role: lead

NCT02031432Phase 3Completed

CORAL XT - Open-label Extension Trial of the CORAL Trial

Role: lead

NCT03882762Phase 1Completed

A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

Role: lead

NCT03958123Phase 1Completed

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

Role: lead

NCT01709214Phase 2Completed

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Role: lead

NCT03757559Phase 1Completed

A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users

Role: lead